Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis

AccesswireSep 9 19:30

Quantum Biopharma Regains Nasdaq Compliance

Seeking AlphaSep 9 13:35

Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80

AccesswireAug 30 22:30

Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update

AccesswireAug 24 07:30

6-K/A: Report of foreign private issuer (related to financial reporting)

SECAug 20 05:23 · Announcements

Top Premarket Gainers

MT NewswiresAug 16 19:54